[go: up one dir, main page]

CN117800299A - Calcium silicate-calcium phosphate crystalline phase composite material and application thereof - Google Patents

Calcium silicate-calcium phosphate crystalline phase composite material and application thereof Download PDF

Info

Publication number
CN117800299A
CN117800299A CN202311836390.1A CN202311836390A CN117800299A CN 117800299 A CN117800299 A CN 117800299A CN 202311836390 A CN202311836390 A CN 202311836390A CN 117800299 A CN117800299 A CN 117800299A
Authority
CN
China
Prior art keywords
calcium
silicate
composite material
phosphate
phase composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311836390.1A
Other languages
Chinese (zh)
Inventor
李向军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Y9 New Material Technology Co.,Ltd.
Original Assignee
Shanghai Ruimanao Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ruimanao Technology Co ltd filed Critical Shanghai Ruimanao Technology Co ltd
Priority to CN202311836390.1A priority Critical patent/CN117800299A/en
Publication of CN117800299A publication Critical patent/CN117800299A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/32Phosphates of magnesium, calcium, strontium, or barium
    • C01B25/325Preparation by double decomposition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24Phosphorous; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25Silicon; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/025Other specific inorganic materials not covered by A61L27/04 - A61L27/12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60Materials for use in artificial skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00Silicon; Compounds thereof
    • C01B33/20Silicates
    • C01B33/24Alkaline-earth metal silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/112Phosphorus-containing compounds, e.g. phosphates, phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/12Materials or treatment for tissue regeneration for dental implants or prostheses
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/70Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/80Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/82Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by IR- or Raman-data
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00Particle morphology
    • C01P2004/01Particle morphology depicted by an image
    • C01P2004/03Particle morphology depicted by an image obtained by SEM
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00Particle morphology
    • C01P2004/51Particles with a specific particle size distribution
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00Particle morphology
    • C01P2004/80Particles consisting of a mixture of two or more inorganic phases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Biomedical Technology (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

The invention discloses a calcium silicate-calcium phosphate crystalline phase composite material and application thereof, wherein the calcium silicate-calcium phosphate crystalline phase composite material is prepared by a preparation method A or a preparation method B; wherein, the preparation method A comprises the following steps: obtaining a mixed system containing tetraethyl silicate, ethanol and water, regulating the pH value of the mixed system to 1-2 by using acid, and then adding calcium salt to obtain a first component; obtaining a mixed system containing phosphate, calcium salt and water to obtain a second component; and uniformly mixing the first component and the second component, stirring at 50-80 ℃, drying at 110-130 ℃ for 11-13h, sintering, cooling, mixing with ethanol, grinding, and sieving to obtain the calcium silicate-calcium phosphate crystalline phase composite material. The calcium silicate-calcium phosphate crystalline phase composite material is a milder active composition and can be applied to the fields of oral cavity, cosmetics and skin mucosa repair.

Description

硅酸钙-磷酸钙晶相复合材料及其应用Calcium silicate-calcium phosphate crystal phase composite materials and their applications

技术领域Technical field

本发明属于复合材料技术领域,具体涉及一种硅酸钙-磷酸钙晶相复合材料及其应用。The invention belongs to the technical field of composite materials, and specifically relates to a calcium silicate-calcium phosphate crystal phase composite material and its application.

背景技术Background technique

硅酸钙类无机活性材料,最早与上世纪90年代,第一次作为主要成分用于新型齿科修复,展现了其良好的抗菌性和生物相容性。随后,大量研究证明硅酸钙类无机活性材料具有良好的生物活性,能够诱导羟基磷灰石(HA)的形成。众多研究结果表明硅酸钙类无机活性材料可以通过自固化过程阻塞牙本质小管,并且能够在生理环境下诱导牙本质再矿化,未来对于用以有效治疗牙本质过敏有很大的可能性。能够有效避免对周围组织造成热损伤;较好的力学强度,能够满足骨修复材料所需的支撑性能;良好的生物相容性和成骨性,可作为可注射的自固化骨修复材料用于牙科和骨科的骨修复手术。此外,硅酸钙类无机活性材料水化过程能够释放出大量Ca(OH)2,其表现出的强碱性能够发挥抗菌抗炎的作用。现有技术中,已经出现了添加硅酸钙类无机活性材料(生物活性玻璃)作为有效活性成分的牙膏,口腔临床研究发现,这类活性成分在使用过程中可以与口腔中的水和唾液发生迅速、持续的反应,释放钙、硅酸根离子,使口腔pH值保持弱碱性,抑制细菌生长,改善口腔内环境,防止细菌在牙釉质表面持续产酸,损坏牙釉质;同时,填充受损牙釉质并使其融合再生,达到修复目的。Calcium silicate inorganic active materials were first used as the main component in new dental restorations in the 1990s, demonstrating their good antibacterial properties and biocompatibility. Subsequently, a large number of studies have proven that calcium silicate inorganic active materials have good biological activity and can induce the formation of hydroxyapatite (HA). Numerous research results have shown that calcium silicate inorganic active materials can block dentinal tubules through a self-curing process and induce dentin remineralization under physiological conditions. They have great potential to be used to effectively treat dentin hypersensitivity in the future. It can effectively avoid thermal damage to surrounding tissues; it has good mechanical strength and can meet the supporting properties required by bone repair materials; it has good biocompatibility and osteogenesis and can be used as an injectable self-curing bone repair material. Bone repair surgery in dentistry and orthopedics. In addition, the hydration process of calcium silicate inorganic active materials can release a large amount of Ca(OH) 2 , and its strong alkalinity can exert antibacterial and anti-inflammatory effects. In the prior art, toothpastes that add calcium silicate inorganic active materials (bioactive glass) as effective active ingredients have appeared. Oral clinical studies have found that such active ingredients can react with water and saliva in the mouth during use. Rapid and sustained reaction, releasing calcium and silicate ions, keeping the oral pH slightly alkaline, inhibiting bacterial growth, improving the oral environment, preventing bacteria from continuing to produce acid on the enamel surface and damaging the enamel; at the same time, the filling is damaged Tooth enamel is fused and regenerated to achieve repair purposes.

但是,进一步的体内外研究揭示,硅酸钙类无机活性材料持续的高碱性环境也对组织修复产生了一定的负面效应。比如在口腔修复中,其对组织的刺激性引起患者的不适和过敏反应,极大的影响了组织修复进度和效果。这些负面效应大大限制了硅酸钙材料在临床的应用。其本质在于硅酸钙材料在分子结构易于水解导致的。However, further in vivo and in vitro studies revealed that the sustained high alkaline environment of calcium silicate inorganic active materials also has certain negative effects on tissue repair. For example, in oral repair, its irritation to tissues can cause discomfort and allergic reactions in patients, which greatly affects the progress and effect of tissue repair. These negative effects greatly limit the clinical application of calcium silicate materials. Its essence lies in the fact that the molecular structure of calcium silicate materials is easily hydrolyzed.

因此,针对上述技术问题,有必要提供一种新的材料来解决上述问题,。Therefore, in view of the above technical problems, it is necessary to provide a new material to solve the above problems.

公开于该背景技术部分的信息仅仅旨在增加对本发明的总体背景的理解,而不应当被视为承认或以任何形式暗示该信息构成已为本领域一般技术人员所公知的现有技术。The information disclosed in this Background section is merely intended to enhance an understanding of the general background of the invention and should not be construed as an admission or in any way implying that the information constitutes prior art that is already known to a person of ordinary skill in the art.

发明内容Summary of the invention

本发明的目的在于提供一种硅酸钙-磷酸钙晶相复合材料,其是一种更加温和的活性组合物,可以应用于口腔领域、化妆品领域以及皮肤粘膜修复领域中。The purpose of the present invention is to provide a calcium silicate-calcium phosphate crystal phase composite material, which is a milder active composition and can be used in the field of oral cavity, cosmetics and skin and mucous membrane repair.

为了实现上述目的,本发明一具体实施例提供的技术方案如下:一种硅酸钙-磷酸钙晶相复合材料,由制备方法A或制备方法B制得;In order to achieve the above object, a technical solution provided by a specific embodiment of the present invention is as follows: a calcium silicate-calcium phosphate crystal phase composite material, prepared by preparation method A or preparation method B;

所述制备方法A包括以下步骤:The preparation method A includes the following steps:

A1、获得含有硅酸四乙酯、乙醇和水的混合体系,用酸将所述混合体系的pH值调节至1-2,再加入钙盐,得到第一组份;A1. Obtain a mixed system containing tetraethyl silicate, ethanol and water, adjust the pH value of the mixed system to 1-2 with acid, and then add calcium salt to obtain the first component;

A2、获得含有磷酸盐、钙盐和水的混合体系,得到第二组份;A2. Obtain a mixed system containing phosphate, calcium salt and water to obtain the second component;

A3、将所述第一组分和第二组份混合均匀后,在50-80℃温度下搅拌后,在110-130℃下干燥11-13h,烧结,冷却后与乙醇混合、研磨、过筛,得到所述硅酸钙-磷酸钙晶相复合材料;A3. Mix the first component and the second component evenly, stir at 50-80°C, dry at 110-130°C for 11-13 hours, sinter, mix with ethanol after cooling, grind and pass Sieve to obtain the calcium silicate-calcium phosphate crystal phase composite material;

所述制备方法B包括以下步骤:The preparation method B includes the following steps:

B1、获得含有磷酸盐、硅酸四乙酯、乙醇、钙盐和水的混合体系,用酸将所述混合体系的pH值调节至1-2,搅拌处理,在110-130℃下干燥36-48h;B1. Obtain a mixed system containing phosphate, tetraethyl silicate, ethanol, calcium salt and water, adjust the pH value of the mixed system to 1-2 with acid, stir, and dry at 110-130°C for 36 -48h;

B2、将干燥后产物烧结,冷却后与乙醇混合、研磨、过筛,得到所述硅酸钙-磷酸钙晶相复合材料。B2. The dried product is sintered, cooled, mixed with ethanol, ground and sieved to obtain the calcium silicate-calcium phosphate crystal phase composite material.

在本发明的一个或多个实施例中,所述磷酸盐为磷酸氢氨、磷酸氢钠以及磷酸二氢钾中至少一种;和/或,In one or more embodiments of the present invention, the phosphate is at least one of ammonium hydrogen phosphate, sodium hydrogen phosphate and potassium dihydrogen phosphate; and/or,

所述钙盐包括水溶性的草酸钙、硝酸钙、柠檬酸钙、葡萄糖酸钙、次氯酸钙、醋酸钙中的至少一种;和/或,The calcium salt includes at least one of water-soluble calcium oxalate, calcium nitrate, calcium citrate, calcium gluconate, calcium hypochlorite, and calcium acetate; and/or,

所述步骤A1和/或步骤B1中,调节混合体系pH值的酸为硝酸、盐酸以及醋酸中的任意一种。In step A1 and/or step B1, the acid used to adjust the pH value of the mixed system is any one of nitric acid, hydrochloric acid and acetic acid.

在本发明的一个或多个实施例中,所述制备方法A和/或制备方法B中的烧结步骤具体包括:In one or more embodiments of the present invention, the sintering step in the preparation method A and/or the preparation method B specifically includes:

将干燥后产物以5-10℃/min的升温速率升温至1200-1400℃后,保温3-6小时。The dried product is heated to 1200-1400°C at a heating rate of 5-10°C/min and kept at this temperature for 3-6 hours.

在本发明的一个或多个实施例中,所述制备方法A的步骤A1中,获得获得含有硅酸四乙酯、乙醇和水的混合体系的步骤包括:In one or more embodiments of the present invention, in step A1 of the preparation method A, the step of obtaining a mixed system containing tetraethyl silicate, ethanol and water includes:

将硅酸四乙酯和乙醇以(0.1-0.4):1的摩尔比混合均匀,并加入水。Tetraethyl silicate and ethanol are mixed uniformly in a molar ratio of (0.1-0.4):1, and water is added.

在本发明的一个或多个实施例中,所述制备方法A的步骤A1中,钙盐与硅酸四乙酯的摩尔比为(0.5-1):1。In one or more embodiments of the present invention, in step A1 of the preparation method A, the molar ratio of calcium salt to tetraethyl silicate is (0.5-1):1.

在本发明的一个或多个实施例中,所述制备方法A的步骤A2中,获得含有磷酸盐、钙盐和水的混合体系的步骤包括:In one or more embodiments of the present invention, in step A2 of the preparation method A, the step of obtaining a mixed system containing phosphate, calcium salt and water includes:

将磷酸盐和钙盐以1:(1-1.5)的摩尔比混合均匀,并溶解于水中。Mix the phosphate and calcium salt evenly at a molar ratio of 1: (1-1.5) and dissolve them in water.

在本发明的一个或多个实施例中,所述制备方法A中,所述第一组分中的硅酸四乙酯与所述第二组分中的磷酸盐的摩尔比为(0.5-2):1。In one or more embodiments of the present invention, in the preparation method A, the molar ratio of tetraethyl silicate in the first component to the phosphate in the second component is (0.5- 2):1.

在本发明的一个或多个实施例中,所述制备方法B中,In one or more embodiments of the present invention, in the preparation method B,

所述磷酸盐与硅酸四乙酯的摩尔比为(0.5-2):1;The molar ratio of the phosphate to tetraethyl silicate is (0.5-2):1;

所述硅酸四乙酯和乙醇的摩尔比为(0.1-0.4):1The molar ratio of tetraethyl silicate to ethanol is (0.1-0.4): 1

所述磷酸盐与钙盐的摩尔比为1:(1-1.5)。The molar ratio of the phosphate to the calcium salt is 1:(1-1.5).

在本发明的一个或多个实施例中,所述制备方法B的步骤B1中的搅拌处理步骤具体为:In one or more embodiments of the present invention, the stirring step in step B1 of the preparation method B is specifically:

当钙盐为弱电解质时,将调节完pH值的混合体系于室温下磁力搅拌50-70min形成白色浆体;或,When the calcium salt is a weak electrolyte, the mixed system after adjusting the pH value is magnetically stirred for 50-70 minutes at room temperature to form a white slurry; or,

当钙盐为强电解质时,将调节完pH值的混合体系于50-80℃恒温水浴下磁力搅拌50-70min形成溶胶态,然后在50-80℃下老化12-36h,形成湿态凝胶。When calcium salt is a strong electrolyte, the mixed system with adjusted pH value is magnetically stirred in a constant temperature water bath at 50-80°C for 50-70 minutes to form a sol state, and then aged at 50-80°C for 12-36 hours to form a wet gel. .

本发明一具体实施例还提供了一种如上述的硅酸钙-磷酸钙晶相复合材料于口腔领域、化妆品领域以及皮肤粘膜修复领域中的应用。A specific embodiment of the present invention also provides an application of the above-mentioned calcium silicate-calcium phosphate crystal phase composite material in the field of oral cavity, cosmetics and skin and mucous membrane repair.

与现有技术相比,本发明的硅酸钙-磷酸钙晶相复合材料,通过上述制备方法A或制备方法B可以使硅酸与磷酸基团的复合相,使用钙盐的强弱电解质,缓慢形成硅酸-磷酸钙前驱体,再通过烧结处理,从而得到一种复合晶相结构的磷酸钙/硅灰石材料,即本发明的硅酸钙-磷酸钙晶相复合材料。Compared with the prior art, the calcium silicate-calcium phosphate crystal phase composite material of the present invention can be made into a composite phase of silicic acid and phosphate groups through the above-mentioned preparation method A or preparation method B, using strong and weak electrolytes of calcium salts, The silicate-calcium phosphate precursor is slowly formed, and then undergoes sintering treatment to obtain a calcium phosphate/wollastonite material with a composite crystal phase structure, that is, the calcium silicate-calcium phosphate crystal phase composite material of the present invention.

附图说明Description of drawings

为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明中记载的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to explain the embodiments of the present invention or the technical solutions in the prior art more clearly, the drawings needed to be used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings in the following description are only These are some embodiments recorded in the present invention. For those of ordinary skill in the art, other drawings can be obtained based on these drawings without exerting creative efforts.

图1为本发明一实施例中硅酸钙-磷酸钙晶相复合材料的制备方法A的流程图;FIG1 is a flow chart of a method A for preparing a calcium silicate-calcium phosphate crystalline composite material in one embodiment of the present invention;

图2为本发明一实施例中硅酸钙-磷酸钙晶相复合材料的制备方法B的流程图;Figure 2 is a flow chart of method B for preparing calcium silicate-calcium phosphate crystal phase composite material in one embodiment of the present invention;

图3为本发明的实施例1-4中硅酸钙-磷酸钙晶相复合材料的XRD图;FIG3 is an XRD diagram of the calcium silicate-calcium phosphate crystalline composite material in Examples 1-4 of the present invention;

图4为本发明的实施例1-4中硅酸钙-磷酸钙晶相复合材料的FTIR光谱图;Figure 4 is an FTIR spectrum of the calcium silicate-calcium phosphate crystal phase composite material in Examples 1-4 of the present invention;

图5为本发明的实施例1-4中硅酸钙-磷酸钙晶相复合材料的SEM照片;FIG5 is a SEM photograph of the calcium silicate-calcium phosphate crystalline composite material in Examples 1-4 of the present invention;

图6为本发明的实施例1-4中硅酸钙-磷酸钙晶相复合材料的粒径分布图;Figure 6 is a particle size distribution diagram of the calcium silicate-calcium phosphate crystal phase composite material in Examples 1-4 of the present invention;

图7为本发明的对比例1中生物玻璃在SBF溶液中反应不同时间后的XRD照片;FIG7 is an XRD photograph of the bioglass in Comparative Example 1 of the present invention after being reacted in the SBF solution for different time periods;

图8为本发明的对比例1中生物玻璃在SBF溶液中反应不同时间后的SEM照片;FIG8 is a SEM photograph of the bioglass in Comparative Example 1 of the present invention after being reacted in the SBF solution for different time periods;

图9为本发明的实施例1-4中硅酸钙-磷酸钙晶相复合材料在SBF溶液中反应不同时间后的SEM照片;Figure 9 is an SEM photo of the calcium silicate-calcium phosphate crystal phase composite material after reacting in SBF solution for different times in Examples 1-4 of the present invention;

图10为本发明的实施例1-4中硅酸钙-磷酸钙晶相复合材料在SBF溶液中反应不同时间后的XRD图。Figure 10 is an XRD pattern of the calcium silicate-calcium phosphate crystal phase composite material after reacting in SBF solution for different times in Examples 1-4 of the present invention.

具体实施方式Detailed ways

为了使本技术领域的人员更好地理解本发明中的技术方案,下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。In order to enable those skilled in the art to better understand the technical solutions in the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described The embodiments are only some of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts should fall within the scope of protection of the present invention.

如图1和2所示,本发明一实施例中的一种硅酸钙-磷酸钙晶相复合材料,由制备方法A或制备方法B制得;As shown in FIGS. 1 and 2 , a calcium silicate-calcium phosphate crystalline composite material in one embodiment of the present invention is prepared by preparation method A or preparation method B;

所述制备方法A包括以下步骤:The preparation method A includes the following steps:

A1、获得含有硅酸四乙酯、乙醇和水的混合体系,用酸将所述混合体系的pH值调节至1-2,再加入钙盐,得到第一组份。A1. Obtain a mixed system containing tetraethyl silicate, ethanol and water, adjust the pH value of the mixed system to 1-2 with acid, and then add calcium salt to obtain the first component.

在步骤A1中,加入钙盐的作用是为了形成弱结合的硅酸钙团簇结构。In step A1, the purpose of adding calcium salt is to form a weakly bound calcium silicate cluster structure.

具体的,获得获得含有硅酸四乙酯、乙醇和水的混合体系的步骤具体可以为:将硅酸四乙酯和乙醇以(0.1-0.4):1的摩尔比混合均匀,并加入水。Specifically, the steps for obtaining a mixed system containing tetraethyl silicate, ethanol and water may be as follows: uniformly mix tetraethyl silicate and ethanol at a molar ratio of (0.1-0.4):1, and add water.

可以理解的是,水是起到溶剂的作用,因此适量水即可,例如水的体积可以与硅酸四乙酯和乙醇混合后的体积和相等,当然也可以多于或少于上述体积和。It can be understood that water acts as a solvent, so an appropriate amount of water is sufficient. For example, the volume of water can be equal to the sum of the volumes after mixing tetraethyl silicate and ethanol. Of course, it can also be more or less than the above-mentioned sum of volumes. .

其中,钙盐与硅酸四乙酯的摩尔比为(0.5-1):1。Among them, the molar ratio of calcium salt to tetraethyl silicate is (0.5-1):1.

其中,调节混合体系pH值的酸为硝酸、盐酸以及醋酸中的任意一种。优选地,使用硝酸调节混合体系pH值。Among them, the acid used to adjust the pH value of the mixed system is any one of nitric acid, hydrochloric acid and acetic acid. Preferably, nitric acid is used to adjust the pH of the mixed system.

A2、获得含有磷酸盐、钙盐和水的混合体系,得到第二组份;A2. Obtain a mixed system containing phosphate, calcium salt and water to obtain the second component;

具体的,获得含有磷酸盐、钙盐和水的混合体系的步骤可以为:将磷酸盐和钙盐以1:(1-1.5)的摩尔比混合均匀,并溶解于水中。可以理解的是,该摩尔比主要是指第二组份中磷和钙的摩尔比。水是起到溶剂的作用,因此适量水即可,例如步骤A2中的水的体积可以步骤A1中水的体积相同,当然也可以多于或少于上述步骤A1中水的体积。Specifically, the step of obtaining a mixed system containing phosphate, calcium salt and water may be: mix the phosphate and calcium salt evenly at a molar ratio of 1: (1-1.5), and dissolve them in water. It can be understood that this molar ratio mainly refers to the molar ratio of phosphorus and calcium in the second component. Water acts as a solvent, so an appropriate amount of water is sufficient. For example, the volume of water in step A2 can be the same as the volume of water in step A1. Of course, it can also be more or less than the volume of water in step A1.

在步骤A2中,加入钙盐的作用是为了形成弱结合的磷酸钙团簇结构。In step A2, the purpose of adding calcium salt is to form a weakly bound calcium phosphate cluster structure.

A3、将所述第一组分和第二组份混合均匀后,在50-80℃温度下搅拌后,在110-130℃下干燥11-13h,烧结,冷却后与乙醇混合、研磨、过筛,得到所述硅酸钙-磷酸钙晶相复合材料。A3. Mix the first component and the second component evenly, stir at 50-80°C, dry at 110-130°C for 11-13 hours, sinter, mix with ethanol after cooling, grind and pass Sieve to obtain the calcium silicate-calcium phosphate crystal phase composite material.

具体的,所述第一组分中的硅酸四乙酯与所述第二组分中的磷酸盐的摩尔比为(0.5-2):1。Specifically, the molar ratio of tetraethyl silicate in the first component to the phosphate in the second component is (0.5-2):1.

具体的,烧结步骤可以具体包括:将干燥后产物以5-10℃/min的升温速率升温至1200-1400℃后,保温3-6小时。其中,烧结步骤可以在马沸炉中进行。Specifically, the sintering step may specifically include: heating the dried product to 1200-1400°C at a heating rate of 5-10°C/min, and then maintaining the temperature for 3-6 hours. Among them, the sintering step can be performed in a Mabo furnace.

具体的,冷却的过程可以为:使烧结的产物在空气中急冷。其中,空气中急冷可以理解为将1200-1400℃的产物直接置于室温以及空气中进行冷却,并冷却至室温。室温可以认为是25℃左右,例如室温可以理解为20-30℃。Specifically, the cooling process may be: quenching the sintered product in air. Among them, quenching in air can be understood as placing the product at 1200-1400°C directly at room temperature and in the air for cooling, and then cooling it to room temperature. Room temperature can be considered to be about 25°C, for example, room temperature can be understood as 20-30°C.

可以理解的是,在制备方法A中,磷酸盐可以为磷酸氢氨、磷酸氢钠以及磷酸二氢钾中至少一种;其中,磷酸氢氨可以认为是磷酸二氢铵或磷酸氢二铵,磷酸氢钠可以认为是磷酸二氢钠或磷酸氢二钠;钙盐包括水溶性的草酸钙、硝酸钙、柠檬酸钙、葡萄糖酸钙、次氯酸钙、醋酸钙中的至少一种。It can be understood that in preparation method A, the phosphate can be at least one of ammonium hydrogen phosphate, sodium hydrogen phosphate and potassium dihydrogen phosphate; wherein, ammonium hydrogen phosphate can be considered to be ammonium hydrogen phosphate or diammonium hydrogen phosphate, Sodium hydrogen phosphate can be considered as sodium hydrogen phosphate or disodium hydrogen phosphate; calcium salts include at least one of water-soluble calcium oxalate, calcium nitrate, calcium citrate, calcium gluconate, calcium hypochlorite, and calcium acetate.

其中,钙盐的选择不同(即钙盐为强电解质或弱电解质),可以导致最终的硅酸钙-磷酸钙晶相复合材料中的组织结构,生物活性等性能的不同。Among them, the choice of calcium salt is different (that is, whether the calcium salt is a strong electrolyte or a weak electrolyte), which can lead to differences in the tissue structure, biological activity and other properties of the final calcium silicate-calcium phosphate crystal phase composite material.

所述制备方法B包括以下步骤:The preparation method B includes the following steps:

B1、获得含有磷酸盐、硅酸四乙酯、乙醇、钙盐和水的混合体系,用酸将所述混合体系的pH值调节至1-2,搅拌处理,在110-130℃下干燥36-48h。B1. Obtain a mixed system containing phosphate, tetraethyl silicate, ethanol, calcium salt and water, adjust the pH value of the mixed system to 1-2 with acid, stir, and dry at 110-130°C for 36 -48h.

具体的,所述磷酸盐与硅酸四乙酯的摩尔比为(0.5-2):1;所述钙盐与硅酸四乙酯的摩尔比为(0.5-1):1;所述磷酸盐与钙盐的摩尔比为1:(1-1.5)。Specifically, the molar ratio of the phosphate to tetraethyl silicate is (0.5-2):1; the molar ratio of the calcium salt to tetraethyl silicate is (0.5-1):1; the phosphoric acid The molar ratio of salt to calcium salt is 1: (1-1.5).

可以理解的是,在制备方法B中,磷酸盐可以为磷酸氢氨、磷酸氢钠以及磷酸二氢钾中至少一种,其中,磷酸氢氨可以认为是磷酸二氢铵或磷酸氢二铵,磷酸氢钠可以认为是磷酸二氢钠或磷酸氢二钠;钙盐包括水溶性的草酸钙、硝酸钙、柠檬酸钙、葡萄糖酸钙、次氯酸钙、醋酸钙中的至少一种。It can be understood that in preparation method B, the phosphate can be at least one of ammonium hydrogen phosphate, sodium hydrogen phosphate and potassium dihydrogen phosphate, wherein the ammonium hydrogen phosphate can be considered to be ammonium hydrogen phosphate or diammonium hydrogen phosphate, Sodium hydrogen phosphate can be considered as sodium hydrogen phosphate or disodium hydrogen phosphate; calcium salts include at least one of water-soluble calcium oxalate, calcium nitrate, calcium citrate, calcium gluconate, calcium hypochlorite, and calcium acetate.

其中,调节混合体系pH值的酸为硝酸、盐酸以及醋酸中的任意一种。优选地,使用硝酸调节混合体系pH值。Among them, the acid used to adjust the pH value of the mixed system is any one of nitric acid, hydrochloric acid and acetic acid. Preferably, nitric acid is used to adjust the pH of the mixed system.

其中,钙盐的选择不同(即钙盐为强电解质或弱电解质),可以导致最终的硅酸钙-磷酸钙晶相复合材料中的组织结构,生物活性等性能的不同。Among them, the choice of calcium salt is different (that is, whether the calcium salt is a strong electrolyte or a weak electrolyte), which can lead to differences in the tissue structure, biological activity and other properties of the final calcium silicate-calcium phosphate crystal phase composite material.

具体的。步骤B1中的搅拌处理步骤具体为:specific. The specific mixing steps in step B1 are:

当钙盐为弱电解质时,将调节完pH值的混合体系于室温下磁力搅拌50-70min形成白色浆体。When the calcium salt is a weak electrolyte, stir the pH-adjusted mixed system magnetically at room temperature for 50-70 minutes to form a white slurry.

当钙盐为强电解质时,将调节完pH值的混合体系于50-80℃恒温水浴下磁力搅拌50-70min形成溶胶态,然后在50-80℃下老化12-36h,形成湿态凝胶。When calcium salt is a strong electrolyte, the mixed system with adjusted pH value is magnetically stirred in a constant temperature water bath at 50-80°C for 50-70 minutes to form a sol state, and then aged at 50-80°C for 12-36 hours to form a wet gel. .

B2、将干燥后产物烧结,冷却后与乙醇混合、研磨、过筛,得到所述硅酸钙-磷酸钙晶相复合材料。B2. The dried product is sintered, cooled, mixed with ethanol, ground and sieved to obtain the calcium silicate-calcium phosphate crystal phase composite material.

具体的,烧结步骤可以具体包括:将干燥后产物以5-10℃/min n的升温速率升温至1200-1400℃后,保温3-6小时。Specifically, the sintering step may include: heating the dried product to 1200-1400°C at a heating rate of 5-10°C/min n, and then maintaining the temperature for 3-6 hours.

具体的,冷却的过程可以为:使烧结的产物在空气中急冷。其中,空气中急冷可以理解为将1200-1400℃的产物直接置于室温以及空气中进行冷却,并冷却至室温。室温可以认为是25℃左右,例如室温可以理解为20-30℃。Specifically, the cooling process may be: quenching the sintered product in air. Among them, quenching in air can be understood as placing the product at 1200-1400°C directly at room temperature and in the air for cooling, and then cooling it to room temperature. Room temperature can be considered to be about 25°C, for example, room temperature can be understood as 20-30°C.

需要说明的是,制备方法A或制备方法B中用到的乙醇可以为无水乙醇;其中的水可以为去离子水。It should be noted that the ethanol used in preparation method A or preparation method B can be absolute ethanol; the water can be deionized water.

本发明一具体实施例还提供了一种如上述的硅酸钙-磷酸钙晶相复合材料于口腔领域、化妆品领域以及皮肤粘膜修复领域中的应用。A specific embodiment of the present invention also provides an application of the above-mentioned calcium silicate-calcium phosphate crystal phase composite material in the field of oral cavity, cosmetics and skin and mucous membrane repair.

下面将结合具体的实施例详细阐述本发明的硅酸钙-磷酸钙晶相复合材料及其应用。The calcium silicate-calcium phosphate crystal phase composite material of the present invention and its application will be described in detail below with reference to specific examples.

实施例1Example 1

首先,将硅酸四乙酯(5.0g)和无水乙醇(100mL)混合均匀,加入到150ml的去离子水中,然后用硝酸调节溶液的pH到1-2,室温下磁力搅拌30min后,再将10.2g草酸钙在溶液中溶解完全,形成A组分。将磷酸氢二铵(3.2g)和草酸钙(5.3g)混合均匀溶解于150ml去离子水中,形成B组分。将A组分与B组分混合均匀后,60℃恒温水浴下磁力搅拌30min,在鼓风干燥箱中120℃下干燥12小时。然后将干燥后粉末放置在马弗炉中,以5℃/min的升温速率升温至1400℃,保温4小时,在空气中急冷。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。First, mix tetraethyl silicate (5.0g) and absolute ethanol (100mL) evenly, add it to 150ml of deionized water, then adjust the pH of the solution to 1-2 with nitric acid, stir magnetically at room temperature for 30 minutes, and then Dissolve 10.2g calcium oxalate completely in the solution to form component A. Mix diammonium hydrogen phosphate (3.2g) and calcium oxalate (5.3g) and dissolve them evenly in 150 ml of deionized water to form component B. After mixing component A and component B evenly, stir magnetically in a constant temperature water bath at 60°C for 30 minutes, and dry in a blast drying oven at 120°C for 12 hours. The dried powder was then placed in a muffle furnace, heated to 1400°C at a heating rate of 5°C/min, kept warm for 4 hours, and quenched in the air. The cooled product was mixed with absolute ethanol, ground in a ball mill at 200 rpm for 2 hours, and sieved to obtain the powder required for the experiment, which is calcium silicate-calcium phosphate crystal phase composite material.

实施例2Example 2

将磷酸氢二铵(3.2g)、硅酸四乙酯(5.1g)、草酸钙(16.2g)和无水乙醇(120ML),以1:1:4.5:5的摩尔比混合均匀后加入到300ML去离子水中,然后用硝酸调节溶液的pH到1-2,室温下磁力搅拌60min形成白色浆体,在鼓风干燥箱中120℃下干燥48小时。然后将干燥后粉末放置在马弗炉中,以5℃/min的升温速率升温至1400℃,保温4小时,在空气中急冷。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。Mix diammonium hydrogen phosphate (3.2g), tetraethyl silicate (5.1g), calcium oxalate (16.2g) and absolute ethanol (120ML) in a molar ratio of 1:1:4.5:5 and add to 300 ML of deionized water, then adjust the pH of the solution to 1-2 with nitric acid, stir magnetically at room temperature for 60 minutes to form a white slurry, and dry in a blast drying oven at 120°C for 48 hours. The dried powder was then placed in a muffle furnace, heated to 1400°C at a heating rate of 5°C/min, kept warm for 4 hours, and quenched in the air. The cooled product was mixed with absolute ethanol, ground in a ball mill at 200 rpm for 2 hours, and sieved to obtain the powder required for the experiment, which is calcium silicate-calcium phosphate crystal phase composite material.

实施例3Example 3

首先,将硅酸四乙酯(5.6g)和无水乙醇(130ML)混合均匀,加入到150ml的去离子水中,然后用硝酸调节溶液的pH到1-2形成SiO2溶胶,再将17.8g硝酸钙在溶液中完全溶解,形成A组分。将3.4g磷酸氢二铵和8.9g硝酸钙混合均匀溶解于150ml去离子水中,形成B组分。将A组分与B组分混合均匀后,60℃恒温水浴下磁力搅拌60min,形成溶胶态,然后在60℃下老化24h,形成湿态凝胶。在鼓风干燥箱中120℃下干燥48小时。然后将干凝胶放置在马弗炉中,以5℃/min的升温速率升温至1400℃,保温4小时,在空气中急冷。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。First, mix tetraethyl silicate (5.6g) and absolute ethanol (130ML) evenly, add it to 150ml of deionized water, then adjust the pH of the solution to 1-2 with nitric acid to form SiO2 sol, and then add 17.8g Calcium nitrate is completely dissolved in the solution to form component A. Mix 3.4g diammonium hydrogen phosphate and 8.9g calcium nitrate and dissolve evenly in 150ml deionized water to form component B. After mixing component A and component B evenly, stir magnetically in a constant temperature water bath at 60°C for 60 minutes to form a sol state, and then age at 60°C for 24 hours to form a wet gel. Dry in a forced air drying oven at 120°C for 48 hours. The xerogel was then placed in a muffle furnace, heated to 1400°C at a heating rate of 5°C/min, kept warm for 4 hours, and quenched in the air. The cooled product was mixed with absolute ethanol, ground in a ball mill at 200 rpm for 2 hours, and sieved to obtain the powder required for the experiment, which is calcium silicate-calcium phosphate crystal phase composite material.

实施例4Example 4

将3.4g磷酸氢二铵、5.3g硅酸四乙酯、26.7g硝酸钙和120ML无水乙醇,混合均匀后加入到300ML去离子水中,然后用硝酸调节溶液的pH到1-2,60℃恒温水浴下磁力搅拌60min形成溶胶态,然后在60℃下老化24h,形成湿态凝胶。在鼓风干燥箱中120℃下干燥48小时。然后将干凝胶放置在马弗炉中,以5℃/min的升温速率升温至1400℃,保温4小时,在空气中急冷。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。Mix 3.4g diammonium hydrogen phosphate, 5.3g tetraethyl silicate, 26.7g calcium nitrate and 120ML absolute ethanol, add them to 300ML deionized water, and then adjust the pH of the solution to 1-2 with nitric acid, 60°C Stir magnetically in a constant temperature water bath for 60 minutes to form a sol state, and then age at 60°C for 24 hours to form a wet gel. Dry in a forced air drying oven at 120°C for 48 hours. The xerogel was then placed in a muffle furnace, heated to 1400°C at a heating rate of 5°C/min, kept warm for 4 hours, and quenched in the air. The cooled product was mixed with absolute ethanol, ground in a ball mill at 200 rpm for 2 hours, and sieved to obtain the powder required for the experiment, which is calcium silicate-calcium phosphate crystal phase composite material.

实施例5Example 5

首先,将4.2硅酸四乙酯和90ML无水乙醇混合均匀,加入到150ml的去离子水中,然后用盐酸调节溶液的pH到1-2,室温下磁力搅拌30min后,再将13.5g草酸钙在溶液中溶解完全,形成A组分。将6.3g磷酸氢二铵和12.3g草酸钙混合均匀溶解于150ml去离子水中,形成B组分。将A组分与B组分混合均匀后,50℃恒温水浴下磁力搅拌30min,在鼓风干燥箱中110℃下干燥13小时。然后将干燥后粉末放置在马弗炉中,以6℃/min的升温速率升温至1300℃,保温3小时,在空气中急冷至室温。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。本实施例中得到的硅酸钙-磷酸钙晶相复合材料与实施例1中得到硅酸钙-磷酸钙晶相复合材料的成分和微观结构大致相同。First, 4.2 g of tetraethyl silicate and 90 ml of anhydrous ethanol were mixed evenly and added to 150 ml of deionized water. Then, the pH of the solution was adjusted to 1-2 with hydrochloric acid. After magnetic stirring for 30 min at room temperature, 13.5 g of calcium oxalate was completely dissolved in the solution to form component A. 6.3 g of diammonium hydrogen phosphate and 12.3 g of calcium oxalate were mixed and evenly dissolved in 150 ml of deionized water to form component B. After component A and component B were mixed evenly, magnetic stirring was performed for 30 min in a 50 ° C constant temperature water bath, and dried at 110 ° C in a blast drying oven for 13 hours. Then, the dried powder was placed in a muffle furnace, heated to 1300 ° C at a heating rate of 6 ° C / min, kept warm for 3 hours, and rapidly cooled to room temperature in air. The cooled product was mixed with anhydrous ethanol and ground in a ball mill at 200 rpm for 2 hours, and the powder required for the experiment was sieved, which was the calcium silicate-calcium phosphate crystalline composite material. The composition and microstructure of the calcium silicate-calcium phosphate crystalline composite material obtained in this example are substantially the same as those of the calcium silicate-calcium phosphate crystalline composite material obtained in Example 1.

实施例6Example 6

首先,将7.8g硅酸四乙酯和150ML无水乙醇混合均匀,加入到150ml的去离子水中,然后用硝酸调节溶液的pH到1-2,室温下磁力搅拌30min后,再将16.8g柠檬酸钙在溶液中溶解完全,形成A组分。将3.5g磷酸氢二铵和6.8g柠檬酸钙混合均匀溶解于150ml去离子水中,形成B组分。将A组分与B组分混合均匀后,80℃恒温水浴下磁力搅拌30min,在鼓风干燥箱中130℃下干燥11小时。然后将干燥后粉末放置在马弗炉中,以10℃/min的升温速率升温至1200℃,保温6小时,在空气中急冷至室温。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。本实施例中得到的硅酸钙-磷酸钙晶相复合材料与实施例1中得到硅酸钙-磷酸钙晶相复合材料的成分和微观结构大致相同。First, 7.8g of tetraethyl silicate and 150ml of anhydrous ethanol were mixed evenly and added to 150ml of deionized water. Then, the pH of the solution was adjusted to 1-2 with nitric acid. After magnetic stirring for 30min at room temperature, 16.8g of calcium citrate was completely dissolved in the solution to form component A. 3.5g of diammonium hydrogen phosphate and 6.8g of calcium citrate were mixed and evenly dissolved in 150ml of deionized water to form component B. After component A and component B were mixed evenly, magnetic stirring was performed for 30min in a constant temperature water bath at 80℃, and dried at 130℃ in a blast drying oven for 11 hours. Then, the dried powder was placed in a muffle furnace, heated to 1200℃ at a heating rate of 10℃/min, kept warm for 6 hours, and rapidly cooled to room temperature in air. The cooled product was mixed with anhydrous ethanol and ground in a ball mill at 200rpm for 2h, and the powder required for the experiment was sieved, which was the calcium silicate-calcium phosphate crystalline composite material. The composition and microstructure of the calcium silicate-calcium phosphate crystalline composite material obtained in this example are substantially the same as those of the calcium silicate-calcium phosphate crystalline composite material obtained in Example 1.

实施例7Example 7

将6.8g磷酸氢二铵、3.2g硅酸四乙酯、18.5g草酸钙和90ML无水乙醇,混合均匀后加入到300ML去离子水中,然后用硝酸调节溶液的pH到1-2,室温下磁力搅拌50min形成白色浆体,在鼓风干燥箱中110℃下干燥40小时。然后将干燥后粉末放置在马弗炉中,以10℃/min的升温速率升温至1300℃,保温3小时,在空气中急冷。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。本实施例中得到的硅酸钙-磷酸钙晶相复合材料与实施例2中得到硅酸钙-磷酸钙晶相复合材料的成分和微观结构大致相同。Mix 6.8g diammonium hydrogen phosphate, 3.2g tetraethyl silicate, 18.5g calcium oxalate and 90ML absolute ethanol, add them to 300ML deionized water, and then adjust the pH of the solution to 1-2 with nitric acid, at room temperature Stir magnetically for 50 minutes to form a white slurry, and dry it in a blast drying oven at 110°C for 40 hours. The dried powder was then placed in a muffle furnace, heated to 1300°C at a heating rate of 10°C/min, kept warm for 3 hours, and quenched in the air. The cooled product was mixed with absolute ethanol, ground in a ball mill at 200 rpm for 2 hours, and sieved to obtain the powder required for the experiment, which is calcium silicate-calcium phosphate crystal phase composite material. The calcium silicate-calcium phosphate crystal phase composite material obtained in this example has approximately the same composition and microstructure as the calcium silicate-calcium phosphate crystal phase composite material obtained in Example 2.

实施例8Example 8

将3.7g磷酸氢二铵、7.9g硅酸四乙酯、16.8g草酸钙和150ML无水乙醇,混合均匀后加入到300ML去离子水中,然后用硝酸调节溶液的pH到1-2,室温下磁力搅拌70min形成白色浆体,在鼓风干燥箱中130℃下干燥36小时。然后将干燥后粉末放置在马弗炉中,以6℃/min的升温速率升温至1200℃,保温6小时,在空气中急冷。将冷却后的产物与无水乙醇混合在球磨机中以200rpm研磨2h,过筛得到实验所需的粉体,即为硅酸钙-磷酸钙晶相复合材料。本实施例中得到的硅酸钙-磷酸钙晶相复合材料与实施例2中得到硅酸钙-磷酸钙晶相复合材料的成分和微观结构大致相同。Mix 3.7g diammonium hydrogen phosphate, 7.9g tetraethyl silicate, 16.8g calcium oxalate and 150ML absolute ethanol, add them to 300ML deionized water, and then adjust the pH of the solution to 1-2 with nitric acid, at room temperature Stir magnetically for 70 minutes to form a white slurry, and dry it in a forced air drying oven at 130°C for 36 hours. The dried powder was then placed in a muffle furnace, heated to 1200°C at a heating rate of 6°C/min, kept warm for 6 hours, and quenched in the air. The cooled product was mixed with absolute ethanol, ground in a ball mill at 200 rpm for 2 hours, and sieved to obtain the powder required for the experiment, which is calcium silicate-calcium phosphate crystal phase composite material. The calcium silicate-calcium phosphate crystal phase composite material obtained in this example has approximately the same composition and microstructure as the calcium silicate-calcium phosphate crystal phase composite material obtained in Example 2.

对比例1Comparative example 1

上海诺晟医疗科技有限公司生产的4510生物活性玻璃(以下简称生物玻璃)。4510 bioactive glass (hereinafter referred to as bioglass) produced by Shanghai Nuosheng Medical Technology Co., Ltd.

下面对实施例1-4中的硅酸钙-磷酸钙晶相复合材料进行如下的测试。The following tests were performed on the calcium silicate-calcium phosphate crystal phase composite materials in Examples 1-4.

(1)X射线衍射仪(XRD)(1)X-ray diffractometer (XRD)

将研磨后的样品,使用XRD仪器进行表征。The ground samples were characterized using XRD instrument.

(2)红外光谱FTIR(2) Infrared spectrum FTIR

将研磨后的样品,取约2mg粉末,加入KBr粉末研磨,压制成片,使用红外光谱仪进行表征。Take about 2 mg of powder from the ground sample, add KBr powder, grind it, press it into tablets, and use an infrared spectrometer for characterization.

(3)Nano粒度(3)Nano particle size

取微量样品放入超纯水中,超声分散均匀,上机测试样品的粒径分布,一组样品测量三次后取平均值。Take a trace amount of sample and put it into ultrapure water, disperse it evenly by ultrasonic, and test the particle size distribution of the sample on the machine. After measuring three times for a group of samples, take the average value.

(4)比表面积及孔径分析(BET)(4) Specific surface area and pore size analysis (BET)

取约200mg干燥粉末样品,脱气温度150℃,时长为5h,脱气结束后上机测试。Take about 200mg of dry powder sample, degassing temperature is 150℃, duration is 5h, and test on the machine after degassing is completed.

(5)扫描电子显微镜(SEM):取微量样品,喷金,使用SEM仪器进行形貌观察。(5) Scanning electron microscope (SEM): Take a trace sample, spray it with gold, and use SEM instrument to observe the morphology.

(6)透射电子显微镜:(6) Transmission electron microscope:

取微量样品加入无水乙醇中,超声2h使其分散均匀,将分散好的悬液滴在碳膜铜网上,自然晾干后上机检测样品。Take a trace amount of the sample and add it to absolute ethanol, ultrasonic for 2 hours to disperse it evenly, drop the dispersed suspension on the carbon film copper mesh, dry it naturally and put it on the machine to test the sample.

其中,部分测试数据如表1所示:Among them, some test data are shown in Table 1:

表1Table 1

为了便于描述,用R-01代表实施例1,R-02代表实施例2,R-03代表实施例3,R-04代表实施例4。For ease of description, R-01 represents Embodiment 1, R-02 represents Embodiment 2, R-03 represents Embodiment 3, and R-04 represents Embodiment 4.

图3为实施例1-4中硅酸钙-磷酸钙晶相复合材料的XRD图,从图1中的XRD图可以看出,R-01的物相组成主要为硅酸二钙(C2S),R-02与R-04的物相为C2S和氧化钙(CaO),R-03可能含有α-TCP与硅酸三钙(C3S)物相组分,此外还存在氧化钙和C2S的衍射峰。典型的无定态结构,是一种无定形的非晶态材料,在XRD中特征峰通常较宽,这是由于无定形材料中的原子排列无序性导致的。Figure 3 is the XRD pattern of the calcium silicate-calcium phosphate crystal phase composite material in Examples 1-4. It can be seen from the XRD pattern in Figure 1 that the phase composition of R-01 is mainly dicalcium silicate (C2S) , the phases of R-02 and R-04 are C2S and calcium oxide (CaO), R-03 may contain α-TCP and tricalcium silicate (C3S) phase components, in addition there is diffraction of calcium oxide and C2S peak. A typical amorphous structure is an amorphous amorphous material. The characteristic peaks in XRD are usually broad, which is caused by the disordered arrangement of atoms in the amorphous material.

图4为实施例1-4中硅酸钙-磷酸钙晶相复合材料的FTIR光谱图,在约1000-1300cm-1范围内,通常有一个强烈的峰出现,代表了硅氧键(Si-O)的伸缩振动。1099cm-1处的反射峰是Si-O伸缩振动;993cm-1处的反射峰是P-O伸缩振动峰;在约450-600cm-1范围内,通常有一个弱峰出现,代表了硅氧键的弯曲振动,这个特征峰可以用来判断材料中硅氧键的存在和结构。Figure 4 is the FTIR spectrum of the calcium silicate-calcium phosphate crystal phase composite material in Examples 1-4. In the range of about 1000-1300 cm -1 , there is usually a strong peak, which represents the silicon-oxygen bond (Si- O) stretching vibration. The reflection peak at 1099cm -1 is Si-O stretching vibration; the reflection peak at 993cm -1 is PO stretching vibration peak; in the range of about 450-600cm -1 , there is usually a weak peak, which represents the silicon-oxygen bond. Bending vibration, this characteristic peak can be used to determine the existence and structure of silicon-oxygen bonds in the material.

图5为实施例1-4中硅酸钙-磷酸钙晶相复合材料的SEM图片,图6为实施例1-4中硅酸钙-磷酸钙晶相复合材料的粒径分布图。从SEM图中可以看到,各组粉体的微观形貌均呈现出不规则片状,样品的颗粒平均尺寸小于5μm。R-01和R-02粒径分布集中在1100nm左右,R-03平均粒径在500nm左右,R-04平均粒径在1000nm左右。Figure 5 is an SEM picture of the calcium silicate-calcium phosphate crystal phase composite material in Example 1-4, and Figure 6 is a particle size distribution diagram of the calcium silicate-calcium phosphate crystal phase composite material in Example 1-4. It can be seen from the SEM images that the microscopic morphology of each group of powders shows irregular flakes, and the average particle size of the samples is less than 5 μm. The particle size distribution of R-01 and R-02 is concentrated around 1100nm, the average particle size of R-03 is around 500nm, and the average particle size of R-04 is around 1000nm.

下面对实施例1-4中的硅酸钙-磷酸钙晶相复合材料以及对比例1中的生物玻璃进行生物活性测试:The following bioactivity tests are performed on the calcium silicate-calcium phosphate crystal phase composite materials in Examples 1-4 and the bioglass in Comparative Example 1:

SBF溶液按照T/CSBM 0027—2022标准配制,现配现用。将15ml SBF溶液加入聚乙烯瓶中,各组样品精确称得0.05g,将其倒入瓶中,并固定于恒温摇床中,在37℃,165rpm的速度摇动聚乙烯瓶。各组样品分别振荡8h、1d、3d、5d。在振荡不同时间后,将反应后的SBF溶液连同样品粉末一起用滤纸过滤,滤出的样品粉末用丙酮冲洗,以阻断反应。将粉末置于95℃烘箱中烘干1小时,密封于样品袋中,于干燥器中保存用于FTIR、XRD及SEM分析。将对应不同反应时间的SBF溶液分别取样,置于冰箱中冷冻保存,用于溶液的ICP测试。The SBF solution is prepared in accordance with T/CSBM 0027-2022 standards and is ready for use. Add 15 ml of SBF solution into the polyethylene bottle. Accurately weigh 0.05g of each group of samples, pour it into the bottle, and fix it in a constant temperature shaker. Shake the polyethylene bottle at 37°C and 165 rpm. Each group of samples was shaken for 8h, 1d, 3d, and 5d respectively. After shaking for different times, the reacted SBF solution together with the sample powder was filtered through filter paper, and the filtered sample powder was rinsed with acetone to block the reaction. The powder was dried in an oven at 95°C for 1 hour, sealed in a sample bag, and stored in a desiccator for FTIR, XRD and SEM analysis. SBF solutions corresponding to different reaction times were sampled and stored in the refrigerator for ICP testing of the solutions.

图7为对比例1中的生物玻璃在SBF溶液中反应不同时间后的XRD图,图8为对比例1中的生物玻璃在SBF溶液中反应不同时间后的SEM照片。由图8的SEM图可见,材料在SBF中分别浸泡3d(3天)、5d(5天)后,材料的表面显微形貌均发生明显改变。材料表面不同的形貌可能是矿化形成的羟基磷灰石形貌,材料表面为钙磷化合物的核化提供了有利的成核位。由图7的XRD图显示材料在SBF溶液中反应3d(3天)后的XRD图谱在2θ=32°左右处出现弥散的磷灰石衍射峰,是由于材料表面在生物矿化过程中生成低结晶度羟基磷灰石所致。Figure 7 is an XRD pattern of the bioglass in Comparative Example 1 after reacting in SBF solution for different times. Figure 8 is an SEM photo of the bioglass in Comparative Example 1 after being reacted in SBF solution for different times. It can be seen from the SEM image in Figure 8 that after the material was soaked in SBF for 3 days (3 days) and 5 days (5 days), the surface micromorphology of the material changed significantly. The different morphologies on the surface of the material may be the morphology of hydroxyapatite formed by mineralization, and the surface of the material provides a favorable nucleation site for the nucleation of calcium-phosphorus compounds. The XRD pattern in Figure 7 shows that the XRD pattern of the material after reacting in SBF solution for 3 days (3 days) has a diffuse apatite diffraction peak at around 2θ = 32°. This is due to the low levels of low energy generated on the surface of the material during the biomineralization process. Crystallinity of hydroxyapatite.

图9为实施例1-4中硅酸钙-磷酸钙晶相复合材料在SBF溶液中反应不同时间后的SEM照片。由图9的SEM图可见,各组材料在SBF中分别浸泡3d(3天)、5d(5天)后,材料的表面显微形貌均发生明显改变。材料表面不同的形貌可能是矿化形成的羟基磷灰石形貌,这种形貌形成的原因可能是溶液中Ca2+、PO4 3-、OH-及CO3 2-等离子扩散进入材料表面的微电层内,促进HCA的核化,材料表面为钙磷化合物的核化提供了有利的成核位。Figure 9 is an SEM photo of the calcium silicate-calcium phosphate crystal phase composite material in Example 1-4 after reacting in SBF solution for different times. It can be seen from the SEM image in Figure 9 that after each group of materials was soaked in SBF for 3 days (3 days) and 5 days (5 days), the surface micromorphology of the materials changed significantly. The different morphologies on the surface of the material may be the morphology of hydroxyapatite formed by mineralization. The reason for the formation of this morphology may be the diffusion of Ca 2+ , PO 4 3- , OH - and CO 3 2- plasma into the material. The microelectric layer on the surface promotes the nucleation of HCA, and the surface of the material provides a favorable nucleation site for the nucleation of calcium-phosphorus compounds.

图10为实施例1-4中硅酸钙-磷酸钙晶相复合材料在SBF溶液中反应不同时间后的XRD图。由图10可见,各组材料在SBF溶液中反应3d(3天)后的XRD图谱在2θ=32°左右处有一尖锐衍射峰,是由于材料表面在生物矿化过程中生成低结晶度羟基磷灰石所致,而原始样品R-01、R-02、R-03和R-04的XRD图谱没有此衍射峰,说明R-01、R-02、R-03和R-04的样品表面生成羟基磷灰石较多。Figure 10 is the XRD pattern of the calcium silicate-calcium phosphate crystal phase composite material in Example 1-4 after reacting in SBF solution for different times. As can be seen from Figure 10, the XRD pattern of each group of materials after reacting in SBF solution for 3 days (3 days) has a sharp diffraction peak at around 2θ = 32°. This is due to the low crystallinity hydroxyphosphorus generated on the surface of the materials during the biomineralization process. Caused by limestone, while the XRD patterns of the original samples R-01, R-02, R-03 and R-04 do not have this diffraction peak, indicating that the surface of the samples of R-01, R-02, R-03 and R-04 More hydroxyapatite is generated.

综合图7-10所示,该实施例样品与对照样均生成了不同程度的磷灰石矿化物。本发明实施例1-4的硅酸钙-磷酸钙晶相复合材料具有和生物玻璃同样的再矿化能力。As shown in Figures 7-10, both the sample of this example and the control sample generated apatite mineralization to varying degrees. The calcium silicate-calcium phosphate crystal phase composite materials of Examples 1-4 of the present invention have the same remineralization ability as biological glass.

浸泡测试:Soak test:

设备:电子天平精度0.01g;酸度计分度值不大于0.02pH单位,配有玻璃电极和参比电极。配有聚四氟乙烯包裹的搅拌转子的磁力一台。Equipment: Electronic balance with an accuracy of 0.01g; acidometer with a graduation value not greater than 0.02 pH units, equipped with glass electrodes and reference electrodes. Magnetic station equipped with a Teflon-coated stirring rotor.

称(2.50±0.01)g取实施例1-4中的硅酸钙-磷酸钙晶相复合材料以及对比例1中的生物玻璃分别置于47.5±0.01)g的蒸馏水,浸泡12h,然后测试pH值(在磁力搅拌下于20℃用酸度计测量,待酸度计示值稳定后读数。),得到如下表所示的数据:Weigh (2.50±0.01) g of the calcium silicate-calcium phosphate crystalline composite materials in Examples 1-4 and the bioglass in Comparative Example 1 and place them in 47.5±0.01) g of distilled water, soak for 12 hours, and then test the pH value (measured with an acidity meter at 20° C. under magnetic stirring, and read the value after the acidity meter reading stabilizes). The data shown in the following table are obtained:

样品sample pH值/浸泡12h后pH value/after soaking for 12 hours 对比例1Comparative example 1 12.812.8 实施例1Example 1 8.78.7 实施例2Example 2 8.68.6 实施例3Example 3 8.28.2 实施例4Example 4 8.58.5

从上表的数据可以看出本发明的实施例1-4中制得硅酸钙-磷酸钙晶相复合材料比相较于对比例1中生物玻璃,在浸泡12h后,具备更加温和的碱性环境,即碱性若于对比例1中生物玻璃,将本发明的硅酸钙-磷酸钙晶相复合材料应用于口腔领域皮肤粘膜修复领域中,降低了对组织修复进度和效果的影响。From the data in the above table, it can be seen that the calcium silicate-calcium phosphate crystalline composite materials prepared in Examples 1-4 of the present invention have a milder alkaline environment after immersion for 12 hours than the bioglass in Comparative Example 1, that is, the alkalinity is lower than that of the bioglass in Comparative Example 1. The calcium silicate-calcium phosphate crystalline composite materials of the present invention are applied to the field of skin and mucosal repair in the oral field, which reduces the impact on the progress and effect of tissue repair.

综上所述,发明人大量实验以及偶然性的发现,以金属醇盐为原料,在酸性条件下,使用钙盐的电解质盐稳定其凝胶态;同时加入磷酸基团,形成硅酸与磷酸基团的复合相。进一步复合弱结晶的钙盐团簇,缓慢形成硅酸-磷酸钙前驱体。通过将二者混合烧结成功制备出一种硅酸钙-磷酸钙晶相复合材料,通过在调整二者的比例关系可以调节其组织结构,生物活性和降解性能,从而根据实际需求制备合适性能的生物材料。In summary, the inventor made extensive experiments and accidental discoveries, using metal alkoxide as raw material, and using calcium salt electrolyte salt to stabilize its gel state under acidic conditions; at the same time, phosphate groups were added to form silicic acid and phosphate groups. The composite phase of the group. Weakly crystalline calcium salt clusters are further compounded to slowly form a silicate-calcium phosphate precursor. By mixing and sintering the two, a calcium silicate-calcium phosphate crystal phase composite material was successfully prepared. By adjusting the proportion of the two, its organizational structure, biological activity and degradation properties can be adjusted, thereby preparing materials with appropriate properties according to actual needs. biomaterials.

对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。不应将权利要求中的任何附图标记视为限制所涉及的权利要求。It will be apparent to those skilled in the art that the invention is not limited to the details of the exemplary embodiments described above and that the invention can be implemented in other specific forms without departing from the spirit or essential features of the invention. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of the invention is defined by the appended claims rather than the foregoing description, and it is intended that all variations falling within the meaning and range of equivalent elements of the claims be included in the invention. Any reference numeral in a claim should not be considered as limiting the claim to which it relates.

此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。In addition, it should be understood that although this specification is described in terms of implementations, not each implementation only contains an independent technical solution. This description of the specification is only for the sake of clarity, and those skilled in the art should take the specification as a whole. , the technical solutions in each embodiment can also be appropriately combined to form other implementations that can be understood by those skilled in the art.

Claims (10)

1. The calcium silicate-calcium phosphate crystalline phase composite material is characterized by being prepared by a preparation method A or a preparation method B;
the preparation method A comprises the following steps:
a1, obtaining a mixed system containing tetraethyl silicate, ethanol and water, regulating the pH value of the mixed system to 1-2 by using acid, and then adding calcium salt to obtain a first component;
a2, obtaining a mixed system containing phosphate, calcium salt and water to obtain a second component;
a3, uniformly mixing the first component and the second component, stirring at 50-80 ℃, drying at 110-130 ℃ for 11-13h, sintering, cooling, mixing with ethanol, grinding, and sieving to obtain the calcium silicate-calcium phosphate crystalline phase composite material;
the preparation method B comprises the following steps:
b1, obtaining a mixed system containing phosphate, tetraethyl silicate, ethanol, calcium salt and water, regulating the pH value of the mixed system to 1-2 by using acid, stirring, and drying at 110-130 ℃ for 36-48h;
and B2, sintering the dried product, cooling, mixing with ethanol, grinding, and sieving to obtain the calcium silicate-calcium phosphate crystalline phase composite material.
2. The calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, wherein the phosphate is at least one of ammonium hydrogen phosphate, sodium hydrogen phosphate, and potassium dihydrogen phosphate; and/or the number of the groups of groups,
the calcium salt comprises at least one of water-soluble calcium oxalate, calcium nitrate, calcium citrate, calcium gluconate, calcium hypochlorite and calcium acetate; and/or the number of the groups of groups,
in the step A1 and/or the step B1, the acid for adjusting the pH value of the mixed system is any one of nitric acid, hydrochloric acid and acetic acid.
3. The calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, characterized in that the sintering step in preparation method a and/or preparation method B specifically comprises:
heating the dried product to 1200-1400 ℃ at a heating rate of 5-10 ℃/min, and preserving the heat for 3-6 hours.
4. The calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, wherein in step A1 of the preparation method a, the step of obtaining a mixed system containing tetraethyl silicate, ethanol and water comprises:
tetraethyl silicate and ethanol in the ratio of (0.1-0.4): 1, and adding water.
5. The calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, wherein in step A1 of the preparation method a, the molar ratio of calcium salt to tetraethyl silicate is (0.5-1): 1.
6. The calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, wherein in step A2 of the preparation method a, the step of obtaining a mixed system containing phosphate, calcium salt and water comprises:
phosphate and calcium salt were combined at 1: (1-1.5) and is dissolved in water.
7. The calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, wherein in the preparation method a, the molar ratio of tetraethyl silicate in the first component to phosphate in the second component is (0.5-2): 1.
8. the calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, wherein in the preparation method B,
the mole ratio of the phosphate to the tetraethyl silicate is (0.5-2): 1, a step of;
the molar ratio of the tetraethyl silicate to the ethanol is (0.1-0.4): 1
The molar ratio of the phosphate to the calcium salt is 1: (1-1.5).
9. The calcium silicate-calcium phosphate crystalline phase composite material according to claim 1, wherein the stirring treatment step in step B1 of the preparation method B is specifically:
when the calcium salt is weak electrolyte, magnetically stirring the mixed system with the pH value adjusted at room temperature for 50-70min to form white slurry; or alternatively, the first and second heat exchangers may be,
when the calcium salt is strong electrolyte, magnetically stirring the mixed system with the pH value regulated in a constant-temperature water bath at 50-80 ℃ for 50-70min to form a sol state, and then aging for 12-36h at 50-80 ℃ to form wet gel.
10. Use of a calcium silicate-calcium phosphate crystalline phase composite according to any one of claims 1-9 in the field of the oral cavity, in the field of cosmetics and in the field of skin mucosa repair.
CN202311836390.1A 2023-12-28 2023-12-28 Calcium silicate-calcium phosphate crystalline phase composite material and application thereof Pending CN117800299A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311836390.1A CN117800299A (en) 2023-12-28 2023-12-28 Calcium silicate-calcium phosphate crystalline phase composite material and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311836390.1A CN117800299A (en) 2023-12-28 2023-12-28 Calcium silicate-calcium phosphate crystalline phase composite material and application thereof

Publications (1)

Publication Number Publication Date
CN117800299A true CN117800299A (en) 2024-04-02

Family

ID=90429153

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311836390.1A Pending CN117800299A (en) 2023-12-28 2023-12-28 Calcium silicate-calcium phosphate crystalline phase composite material and application thereof

Country Status (1)

Country Link
CN (1) CN117800299A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101157045A (en) * 2007-10-26 2008-04-09 中国科学院上海硅酸盐研究所 Bioactive calcium phosphate/tricalcium silicate composite self-curing material, method and application
CN101367525A (en) * 2008-09-19 2009-02-18 中国科学院上海硅酸盐研究所 Sodium calcium silicate biological material, preparation method and use thereof
EP2236477A1 (en) * 2009-04-03 2010-10-06 Shinn Jyh Ding Calcium silicate-based composite cement and methods for the preparation
US20110021338A1 (en) * 2008-01-09 2011-01-27 University Court Of The University Of Aberdeen Synthesis of bioceramic compositions
US20160022864A1 (en) * 2014-07-22 2016-01-28 Chia-Tze Kao Tiny Bone Defect Repairing Material, Matrix Material Thereof and Producing Method Thereof
BR112013004354A2 (en) * 2010-09-10 2016-05-10 Unilever Nv particulate matter and its production method
CN109503146A (en) * 2018-11-30 2019-03-22 中国科学院上海硅酸盐研究所 A kind of the hydro-thermal method preparation and its application of ultra-fine silicon calcium phosphate powder

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101157045A (en) * 2007-10-26 2008-04-09 中国科学院上海硅酸盐研究所 Bioactive calcium phosphate/tricalcium silicate composite self-curing material, method and application
US20110021338A1 (en) * 2008-01-09 2011-01-27 University Court Of The University Of Aberdeen Synthesis of bioceramic compositions
CN101367525A (en) * 2008-09-19 2009-02-18 中国科学院上海硅酸盐研究所 Sodium calcium silicate biological material, preparation method and use thereof
EP2236477A1 (en) * 2009-04-03 2010-10-06 Shinn Jyh Ding Calcium silicate-based composite cement and methods for the preparation
BR112013004354A2 (en) * 2010-09-10 2016-05-10 Unilever Nv particulate matter and its production method
US20160022864A1 (en) * 2014-07-22 2016-01-28 Chia-Tze Kao Tiny Bone Defect Repairing Material, Matrix Material Thereof and Producing Method Thereof
CN109503146A (en) * 2018-11-30 2019-03-22 中国科学院上海硅酸盐研究所 A kind of the hydro-thermal method preparation and its application of ultra-fine silicon calcium phosphate powder

Similar Documents

Publication Publication Date Title
Ishikawa et al. Sol–gel synthesis of calcium phosphate-based biomaterials—A review of environmentally benign, simple, and effective synthesis routes
EP0688202B1 (en) Calcium phosphate hydroxyapatite precursor and methods for making and using the same
CN102639159B (en) Ion substituted calcium phosphate particles
CN102438667B (en) Calcium gallium phosphate biomaterial
ES2321411T3 (en) OXIAPATITA REPLACED WITH SILICON.
CN105194728A (en) Degradable bioactive porous ceramic material, preparation method and application of degradable bioactive porous ceramic material
CN101695584A (en) Injectable composite material capable of promoting bone regeneration and repair and preparation method thereof
JP6435542B2 (en) Synthesis of bioceramic compositions
CN104192817B (en) Utilize the method for the high specific surface area and mesoporous hydroxyapatite nano particle of template synthesis
Kaur et al. Sol-gel derived strontium-doped SiO2–CaO–MgO–P2O5 bioceramics for faster growth of bone like hydroxyapatite and their in vitro study for orthopedic applications
JP5577536B2 (en) Medical materials
Degli Esposti et al. Composite materials of amorphous calcium phosphate and bioactive glass nanoparticles for preventive dentistry
CN108421085B (en) Graphene and hydroxyapatite composite bionic bone material and preparation method thereof
CN103979945B (en) A kind of preparation method of bioactive wollastonite ceramics
TW200934461A (en) Calcium silicate-based cements and manufacturing method thereof
CN117800299A (en) Calcium silicate-calcium phosphate crystalline phase composite material and application thereof
CN104261815B (en) The preparation method of a kind of fluorine silicon sodium composite mixed HA biological ceramics nano-powder
CN119587772A (en) Preparation method and application of manganese-containing bioglass composite membrane material
Hafezi et al. Preparation and characterization of whitlockite-merwinite nanocomposite
CN112174152B (en) Polyion co-doped tetracalcium phosphate powder, synthesis method and application
CN106747385A (en) A kind of ceramic material and preparation method thereof
CN103253932B (en) Silicon calcium phosphate biomaterial, preparation method and uses thereof
CN113979729A (en) A kind of lithium silicon compound enhanced bioactive ceramic material and preparation method thereof
Wang et al. A monetite/amorphous silica complex for long-term dentine hypersensitivity treatment through the acid stability and mineralization promoting effect of silica
TWI883553B (en) Glass ceramic and manufacturing method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250417

Address after: Building C, No.888, Huanhu West 2nd Road, Lingang New District, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: Shanghai Y9 New Material Technology Co.,Ltd.

Country or region after: China

Address before: 201400 floor 5, building 11, No. 6055, Jinhai highway, Fengxian District, Shanghai

Applicant before: Shanghai Ruimanao Technology Co.,Ltd.

Country or region before: China